Aspect Biosystems and Novo Nordisk partner with $75m deal to develop bioprinted tissue therapeutics

pharmafile | April 13, 2023 | News story | Research and Development  

Canadian biotech company Aspect Biosystems and Denmark-based Novo Nordisk have announced a collaboration, development and license agreement to develop bioprinted tissue therapeutics designed to replace, repair or supplement biological functions inside the body.


Aspect will offer its proprietary bioprinting technology, which has developed cell-based medicine designed to be biologically functional, immune-protective and suitable for surgical implantation. This will be combined with Novo Nordisk’s expertise and technology in stem cell differentiation, which is used to find cells to replace damaged and lost ones, and cell therapy development and manufacture.


Within the partnership, Aspect will receive $75m in initial payments and up to $650m in future milestone payments per product created from the collaboration, plus tiered royalties.


Tamer Mohamed, chief executive officer of Aspect Biosystems, commented: “We are thrilled to partner with Novo Nordisk, a global leader and pioneer in the fight against diabetes and chronic diseases, to create breakthrough therapeutics that could transform the lives of millions of people around the world. This partnership leverages Aspect’s full-stack tissue therapeutic platform, talented team and bold vision, and reinforces our strategy to create bioprinted tissue therapeutics through partnerships with global industry leaders while also advancing our internal therapeutic pipeline.”


“Novo Nordisk has built strong capabilities when it comes to producing functional and highly pure therapeutic replacement cells at the highest quality and at scale. Collaborating with Aspect Biosystems adds an important component to our strategy to develop comprehensive cell therapy products. We are excited to co-develop solutions for cell therapy delivery that could lead to life-changing treatments for those living with a serious chronic disease,” said Jacob Sten Petersen, corporate vice president and head of Cell Therapy R&D at Novo Nordisk.


James Spargo

Related Content

No items found

Latest content